Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial
美普拉珠单抗（一种 CD147 抗体）治疗重症 COVID-19：一项双盲、随机、安慰剂对照的 3 期临床试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02208-9
Bian, Huijie; Chen, Liang; Zhang, Zheng; Wen, Ai-Dong; Zheng, Zhao-Hui; Song, Li-Qiang; Yao, Meng-Ying; Liu, Ying-Xia; Zhang, Xi-Jing; Dong, Hong-Lin; Lian, Jian-Qi; Pan, Lei; Liu, Yu; Gu, Xing; Zhao, Hui; Wang, Jing-Wen; Wang, Qing-Yi; Zhang, Kui; Jia, Jun-Feng; Xie, Rong-Hua; Luo, Xing; Fu, Xiang-Hui; Jia, Yan-Yan; Hou, Jun-Na; Tan, Qiu-Yue; Chen, Xiao-Xia; Yang, Liu-Qing; Lin, Yuan-Long; Wang, Xiao-Xia; Zhang, Lei; Zeng, Qin-Jing; Li, Wen-Jie; Wang, Rui-Xuan; Zhang, Yang; Sun, Xiu-Xuan; Wang, Bin; Yang, Xu; Jiang, Jian-Li; Li, Ling; Wu, Jiao; Yang, Xiang-Min; Zhang, Hai; Shi, Ying; Chen, Xiao-Chun; Tang, Hao; Shi, Hong-Wei; Liu, Shuang-Shuang; Yang, Yong; Yang, Tian-Yi; Wei, Ding; Chen, Zhi-Nan; Zhu, Ping
